SBIR Phase II: Genomic Mapping of DNA by Means of GeneEngine(TM) Technology

Information

  • NSF Award
  • 0320449
Owner
  • Award Id
    0320449
  • Award Effective Date
    8/1/2003 - 21 years ago
  • Award Expiration Date
    7/31/2007 - 17 years ago
  • Award Amount
    $ 999,998.00
  • Award Instrument
    Standard Grant

SBIR Phase II: Genomic Mapping of DNA by Means of GeneEngine(TM) Technology

This Small Business Innovation Research Phase II project aims to build a technology for long-range, high-resolution DNA mapping based on the proprietary GeneEngine(TM) platform. This technology will be a unique tool for genomics because of the combination of features: single- molecule sensitivity, ability to analyze very long DNA molecules, high throughput, and potential for automation. The basic feasibility of this technology was shown in Phase I. The Phase II project is aimed at creating efficient procedures for sample preparation and measurement, as well as for developing analysis algorithms and combining them into an automated software package. These procedures and software will be united to form a toolkit for DNA mapping.<br/><br/>The commercial application of this project will be in the area of Genomics. The product resulting from this project will comprise of instruments and consumables (e.g. reagents) for mapping of whole microbial genomes based on long-range, single-molecule DNA mapping. The ability to scan microbial genomic DNA for genetic information at a fraction of the cost and time of that needed currently will be valuable in a number of commercial applications in life science research and the healthcare industry, including the elucidation of complex genetic pathways, identification of target genes for development of novel anti-infective drugs, correlation of genomic information with unique functions and with drug response, as well as for DNA-based molecular diagnostics and prognostics. The principal market for these applications would be the bio-pharmaceutical companies and academic research laboratories, with additional longer-term markets expected in the area of clinical diagnostics.

  • Program Officer
    F.C. Thomas Allnutt
  • Min Amd Letter Date
    7/18/2003 - 21 years ago
  • Max Amd Letter Date
    7/25/2005 - 19 years ago
  • ARRA Amount

Institutions

  • Name
    U.S. GENOMICS INC
  • City
    WOBURN
  • State
    MA
  • Country
    United States
  • Address
    12 GILL ST
  • Postal Code
    018011743
  • Phone Number
    7819375550

Investigators

  • First Name
    Rudolf
  • Last Name
    Gilmanshin
  • Email Address
    r.gilmanshin@fdsonics.com
  • Start Date
    7/18/2003 12:00:00 AM

FOA Information

  • Name
    Health
  • Code
    203000
  • Name
    Biomaterials-Short & Long Terms
  • Code
    510402